Want to see VTVT full AI Analyst Report?
Top Page
vTv Therapeutics
(NASDAQ:VTVT)
Select Model
Select Model
Rating:53Neutral
Price Target:
$30.00
▼(-11.53% Downside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by mixed financials: a strong, low-leverage balance sheet offsets ongoing losses and negative cash flow. Technical signals are moderately supportive, but the very high P/E provides limited valuation support.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet gives vTv financial flexibility while it advances its pipeline and manages development spending. The substantial equity base relative to assets also reduces fixed financing pressure, allowing capital allocation to remain focused on research and potential value-creating milestones.
Negative Factors
Negative cash generation
Negative operating and free cash flow means the business is not currently self-funding its research activities. Continued cash burn can consume financial resources over the next several quarters and increase dependence on the balance sheet or future external funding before programs produce recurring returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet gives vTv financial flexibility while it advances its pipeline and manages development spending. The substantial equity base relative to assets also reduces fixed financing pressure, allowing capital allocation to remain focused on research and potential value-creating milestones.
Read all positive factors
vTv Therapeutics (VTVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$120.87M
Dividend YieldN/A
Average Volume (3M)44.85K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth216600.00%
EPS Growth75.57%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,953,928
10 Day Avg. Volume43,614
30 Day Avg. Volume44,853
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap3.15
Enterprise Value/Revenue10.33
Enterprise Value/Gross Profit10.33
Enterprise Value/Ebitda-59.56
Forecast
1Y Price Target
$56.80Price Target Upside67.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$36.81M
vTv Therapeutics Business Overview & Revenue Model
Company Description
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, vTv Therapeutics primarily seeks to generate value and potential revenue through the development and advancement of its drug candidates rather than through steady recurring sales from an established p...
vTv Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| Gross Profit | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| EBITDA | -6.39M | -31.06M | -22.52M | -25.86M | -24.77M | -17.52M |
| Net Income | -4.76M | -26.97M | -18.46M | -20.25M | -19.16M | -12.99M |
Balance Sheet | ||||||
| Total Assets | 87.59M | 89.90M | 38.27M | 11.02M | 33.24M | 25.47M |
| Cash, Cash Equivalents and Short-Term Investments | 86.64M | 88.93M | 36.75M | 9.45M | 12.13M | 13.41M |
| Total Debt | 0.00 | 0.00 | 169.00K | 529.00K | 716.00K | 932.00K |
| Total Liabilities | 8.96M | 25.46M | 23.96M | 29.57M | 27.40M | 10.25M |
| Stockholders Equity | 78.63M | 64.44M | 12.20M | -24.68M | -10.74M | -9.74M |
Cash Flow | ||||||
| Free Cash Flow | -16.76M | -25.25M | -25.31M | -19.08M | -15.27M | -19.31M |
| Operating Cash Flow | -16.76M | -25.25M | -25.31M | -19.08M | -15.25M | -19.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 4.40M | -21.00K | 0.00 |
| Financing Cash Flow | 77.48M | 77.44M | 52.61M | 12.00M | 13.98M | 26.98M |
vTv Therapeutics Technical Analysis
Negative
33.91
Price Trends
32.08
Negative
32.96
Negative
34.53
Negative
Market Momentum
-0.47
Negative
44.37
Neutral
52.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Negative. The current price of 33.91 is above the 20-day moving average (MA) of 31.33, above the 50-day MA of 32.08, and below the 200-day MA of 34.53, indicating a bearish trend. The MACD of -0.47 indicates Negative momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 52.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTVT.
vTv Therapeutics Risk Analysis
vTv Therapeutics disclosed 19 risk factors in its most recent earnings report. vTv Therapeutics reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
vTv Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $120.87M | -277.91 | -6.27% | ― | 216600.00% | 75.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $253.47M | -3.13 | -58.00% | ― | ― | ― | |
47 Neutral | $64.09M | -0.69 | -53.22% | ― | ― | 55.84% | |
44 Neutral | $60.34M | -3.44 | -48.25% | ― | ― | 96.65% | |
43 Neutral | $57.99M | -1.15 | 214.97% | ― | -31.12% | -35.10% | |
42 Neutral | $191.36M | -6.04 | -29.09% | ― | 8906.15% | 41.48% |
* Healthcare Sector Average
VTVT
vTv Therapeutics
30.57
7.98
35.33%
ATHE
Alterity Therapeutics
3.45
-0.88
-20.32%
IFRX
InflaRx
1.72
0.21
13.91%
CLNN
Clene
4.08
-6.28
-60.62%
PLRX
Pliant Therapeutics
1.04
-0.46
-30.54%
ADAG
Adagene
2.85
0.86
43.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.